Abstract #LBA76: Hope Rugo presented interim OS results from the P3 TROPiCS-02 trial, which compared sacituzumabgovitecan (SG) (n=272) vs physician’s choice (n=271) in heavily pre-treated HR+/HER2- endocrine-resistant, unresectable locally advanced or metastatic breast cancer.
Results: SGdemonstrated significant improvement in OS (median: 14.4 vs 11.2 months for TPC),and significant improvement in objective response rate (21% vs 14%) and quality of life.
Thought leader reactions were moderately positive, with several welcoming any OS benefit in a population with limited treatment options. Comparisons to recent PFS data were positive:
However, some questioned the importance ofan overall survival benefit of only three months:
Several commentators hope and expect FDA approval for sacituzumab govitecan in this population:
One KOL would like to know the impact of this data on Trop-2 negative breast cancer patients and wonders why Trop-2 expression was not assessed.
This interim analysis of TROPiCS-2 OS data represents a positive step for this small population with limited treatment options. Some, however, consider the data only “incremental” or “modest”instead of game changing. Still, thought leaders expect FDA approval for sacituzumabgovite can in this population.
Synthesis by Opus Strategy, LLC
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm
Artificial Intelligence (AI) has emerged as a transformative technology with the potential to revolutionize various industries, including medicine. One of the most prominent applications of AI in healthcare is the use of ChatGPT, a sophisticated language model developed by OpenAI.
When clinical trials fail to include racial and ethnic diversity into medical research, it can be harmful for large segments of the population. There is a real-world need for clinical oncology trials to adequately represent diverse racial and ethnic groups to better reflect the populations that are most likely to benefit from a drug.